Over time and clinical results, targeted treatments against Covid-19 become clearer.
This is in particular the case of new monoclonal antibodies, resulting from gene therapy, which are in a way specific sera that can reduce the severity and the risk of hospitalization if they are taken very soon after infection, in the week after onset of symptoms.
And if the Eli Lilly laboratory has not continued the approval of its treatment, two other treatments of this type, from Roche and Celltrion Healthcare, have just been authorized in Europe.
Their role is to improve the immune defenses of the people who benefit from them.
Read also
Covid-19: why conditioning the health pass to the third dose is not easy
These treatments are given by a single intravenous injection in the hospital.
Before the arrival of vaccines, they were one of the few glimmers of hope for people who are immunocompromised and those at increased risk of developing severe forms of Covid-19.
In France, they remain relevant for around 130,000 people
This article is for subscribers only.
You have 84% left to discover.
Pushing back the limits of science is also freedom.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
